Literature DB >> 426502

Inappropriate antidiuretic hormone following adenine arabinoside administration.

E Ramos, R F Timmons, S C Schimpff.   

Abstract

A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound hyponatremia secondary to the administration of adenine arabinoside.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 426502      PMCID： PMC352616          DOI： 10.1128/AAC.15.1.142

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Cytosine arabinoside for localized herpes zoster in patients with cancer: failure in a controlled trial.

Authors:  S C Schimpff; C L Fortner; W H Greene; P H Wiernik
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

2.  Cytosine arabinoside therapy for herpesvirus infections.

Authors:  A W Chow; J Foerster; W Hryniuk
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

3.  Serologic and virus-isolation studies of patients with varicella or herpes-zoster infection.

Authors:  E Gold
Journal:  N Engl J Med       Date:  1966-01-27       Impact factor: 91.245

Review 4.  Varicella pneumonia in adults. Report of seven cases and a review of literature.

Authors:  J H Triebwasser; R E Harris; R E Bryant; E R Rhoades
Journal:  Medicine (Baltimore)       Date:  1967-09       Impact factor: 1.889

5.  Acute glomerulonephritis associated with varicella infection.

Authors:  S Minkowitz; R Wenk; E Friedman; A Yuceoglu; S Berkovich
Journal:  Am J Med       Date:  1968-03       Impact factor: 4.965

Review 6.  The syndrome of inappropriate secretion of antidiuretic hormone.

Authors:  F C Bartter; W B Schwartz
Journal:  Am J Med       Date:  1967-05       Impact factor: 4.965

7.  Herpes-zoster meningoencephalitis.

Authors:  F H Norris; R Leonards; P R Calanchini; C D Calder
Journal:  J Infect Dis       Date:  1970-10       Impact factor: 5.226

8.  Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study.

Authors:  R J Whitley; L T Ch'ien; R Dolin; G J Galasso; C A Alford
Journal:  N Engl J Med       Date:  1976-05-27       Impact factor: 91.245

9.  Toxicity of adenine arabinoside in humans.

Authors:  A H Ross; A Julia; C Balakrishnan
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226
  9 in total
  4 in total

1.  Herpes simplex encephalitis: poor outcome despite adenine arabinoside therapy.

Authors:  W M Wenman; J L Brunton; B A Lank; A R Ronald
Journal:  Can Med Assoc J       Date:  1982-04-01       Impact factor: 8.262

2.  Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination.

Authors:  S L Sacks; G H Scullard; R B Pollard; P B Gregory; W S Robinson; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

3.  Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failure.

Authors:  G R Aronoff; J J Szwed; R L Nelson; E L Marcus; S A Kleit
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

4.  Vidarabine-associated encephalopathy and myoclonus.

Authors:  R W Vilter
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.